



FOR IMMEDIATE RELEASE



Contact: Jennifer Ryan
Office of Communications
732/235-9891
ryanje@umdnj.edu

**THE CANCER INSTITUTE OF NEW JERSEY
BRINGS RESEARCH TO LIFE**

*More Than 130 Clinical Trials Offered by
The Cancer Institute of New Jersey (CINJ)*

New Brunswick, N.J., August 2, 2004 – At The Cancer Institute of New Jersey (CINJ), clinical research is key to providing comprehensive cancer care to patients throughout the state. With more than 130 active clinical trials, CINJ is leading the way toward uncovering new methods of treatment and prevention of cancer – quite literally bringing research to life.

Most cancer clinical trials are medical studies that test new treatments and new ways of using existing treatments for cancer. Researchers use these clinical trials to answer questions about a treatment and to make sure it is safe and effective.

There are several types of clinical trials including: treatment, prevention, screening and behavioral. Treatment trials use a drug with the intention of curing, prolonging or improving the life of patients with cancer. Prevention trials test ways of preventing cancer from developing or returning and screening trials study ways to detect cancer in early stages, making treatment more effective. Behavioral trials study quality of life, methods to improve enrollment to clinical trials, and reasons why patients choose different treatment options. Across these categories, CINJ offers clinical trials for breast, prostate, lung, colon, ovarian, bladder, renal, skin, and pediatric cancers, among others.

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, patients at CINJ have access to treatment options not available at other institutions within the state. CINJ currently enrolls more than 1,000 patients in clinical trials or approximately 15% of all new adult cancer patients and approximately 70% of all pediatric cancer patients on clinical trials. Enrollment in clinical trials nationwide is only 2% to 4% of all adult cancer patients.

-more-

“Participation in a clinical trial can help researchers solve some of the mysteries of cancer and improve treatment for future generations,” said Joseph R. Bertino, M.D., Associate Director and Chief Scientific Officer at CINJ and University Professor of Medicine and Pharmacology, UMDNJ-Robert Wood Johnson Medical School. “Clinical research is so important because it has the potential to change the way we look at and treat many types of cancers.”

Several CINJ clinical treatment trials are available at hospitals and doctors’ offices in New Jersey through the CINJ Oncology Group. The CINJ Oncology Group is a network of hospitals and doctors who are Partners and Affiliates of CINJ.

For more information about clinical trials or how you can become involved in one of the many clinical research trials offered at The Cancer Institute of New Jersey and its Partner and Affiliate hospitals and doctors offices, please call 732/235-CINJ or 1-866-654-9898. Information on cancer clinical trials offered at CINJ and throughout the state can also be found on the web at New Jersey Cancer Trial Connect (www.njctc.org).

The Cancer Institute of New Jersey is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. CINJ is dedicated to improving the prevention, detection, treatment and care of patients with cancer. CINJ’s physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice-quite literally bringing research to life. CINJ’s Providers' Network is comprised of twenty-one Partner and Affiliate institutions throughout the state and provides a mechanism to rapidly disseminate important, valid discoveries into the community. The Cancer Institute of New Jersey is part of UMDNJ-Robert Wood Johnson Medical School.

###